09:41 AM EST - BioVaxys Technology Corp : Provides a summary of current operating initiatives including the integration and disposition of assets acquired in February 2024 from the former IMV, Inc., the non-exclusive out-licensing of DPX to human and animal health companies, restarting clinical studies---notably DPX-surMAGE in advanced bladder cancer, expansion of the BioVaxys pipeline a through new formulations based on the DPX™ immune educating platforms, and most recently, the mitigation of risk through the significant reduction of a performance milestone provision in the Asset Purchase Agreement with Horizon Technology Finance Corp. BioVaxys Technology Corp
shares C.BIOV are trading unchanged at $0.04.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACNX&qmodStoryID=4663775000077791
